Evidence map›Paper›PMID 32292131›Full record

ArticleThyroid : official journal of the American Thyroid Association2020

Response to RET-Specific Therapy in

Dora Dias-Santagata, Jochen K Lennerz, Peter M Sadow, Ryan P Frazier, Sandya Govinda Raju, Dahlia Henry, Trisha Chung, Jennifer Kherani, S Michael Rothenberg, Lori J Wirth

Open access · hybridAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Thyroid : official journal of the American Thyroid Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Observational
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Kinase inhibitors in thyroid cancers.Endocrine oncology (Bristol, England) · 2023
    Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Molecular-Driven Therapy in Advanced Thyroid Cancer.Current treatment options in oncology · 2021
    Review
  19. Review
  20. [Systemic treatment of metastasized thyroid cancer-approved treatments and new approaches].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Dora Dias-SantagataDepartment of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Jochen K LennerzDepartment of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Peter M SadowDepartment of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Ryan P FrazierDepartment of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Sandya Govinda RajuLoxo Oncology, Inc., Stamford, Connecticut, USA.
Dahlia HenryLoxo Oncology, Inc., Stamford, Connecticut, USA.
Trisha ChungLoxo Oncology, Inc., Stamford, Connecticut, USA.
Jennifer KheraniLoxo Oncology, Inc., Stamford, Connecticut, USA.
S Michael RothenbergLoxo Oncology, Inc., Stamford, Connecticut, USA.
Lori J WirthDepartment of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Loxo Oncology at Lilly (United States) · USMassachusetts General Hospital · US

Funding

Strategies to Overcome Immune Resistance in Head and Neck CancersP01CA240239 · NCI · YALE UNIVERSITY · PI MEMPEL, THORSTEN ROMAN · 2019 to 2023
$8.4M
NCI NIH HHS P01 CA240239
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AgedAntineoplastic AgentsClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicHigh-Throughput Nucleotide SequencingHumansMaleNeoplasm MetastasisOncogenesPositron Emission Tomography Computed TomographyProtein Kinase InhibitorsProto-Oncogene Proteins c-retPyrazolesPyridinesThyroid Cancer, PapillaryThyroid Carcinoma, AnaplasticAntineoplastic AgentsProtein Kinase InhibitorsProto-Oncogene Proteins c-retPyrazolesPyridinesRET protein, humanselpercatinibanaplastic thyroid carcinomagene fusionLOXO-292RETtumor genomic profiling

Identifiers

PMID32292131
PMCPMC7482117
OpenAlexW3015263888

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.